Sulindac and indomethacin inhibit formation of aberrant crypt foci in the colons of dimethyl hydrazine treated rats

Journal of Gastroenterology and Hepatology (Australia)

Volumn 11, Issue 1, 1996, Pages 88-92

  Charalambous, Dora ^a   Farmer, Chip ^a   O'Brien, Paul E ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Aberrant crypt; Colon cancer; Indomethacin; Rat; Sulindac

Indexed keywords

DIMETHYLHYDRAZINE; INDOMETACIN; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON INJURY; COLORECTAL CANCER; CRYPT CELL; DRUG EFFECT; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0029883613     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1996.tb00016.x     Document Type: Article

References (24)

1. Giardiello FM, Hamilton SR, Krush AJ et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 1993; 328: 1313-16.
2. Labayle D, Fischer D, Vielh P et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-9.
3. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Randomized double blind placebo controlled clinical trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in familial adenomatous polyposis. Br. J. Surg. 1993; 80: 1618-19.
4. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Res. 1993; 53: 1322-27.
5. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl Cancer Inst. 1991; 83: 355-8.
6. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumour development. Cancer Res. 1987; 47: 5340-6.
7. Reddy BS, Tokumo K, Kulkarni N, Algia C, Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992; 13: 1019-23.
8. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A. Inhibition of development of methylnitrosourea-induced rat colon tumours by indomethacin treatment. Cancer Res. 1981; 41: 1954-7.
9. Skinner SA, Penney AG, O'Brien PE. Sulindac inhibits the rate of growth and appearance of colon tumours in the rat. Arch. Surg. 1991; 126: 1094-6.
10. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings. Cancer Lett. 1987; 37: 147-51.
11. Pretlow TP, Barrow BJ, Ashton WS et al. Aberrant crypts: Putative preneoplastic foci in human colonic mucosa. Cancer Res. 1991; 51: 1564-7.
12. McLellan EA, Bird RP. Aberrant crypts: Potential preneoplastic lesions in the murine colon. Cancer Res. 1988; 48: 6187-92.
13. Archer MC, Bruce WR, Chan CC et al. Aberrant crypt foci and microadenoma as markers for colon cancer. Environ. Health Perspect. 1992; 98: 195-7.
14. Sandforth F, Heimpe S, Balzer T, Gutschmidt S, Riecken EO. Characterisation of stereomicroscopically identified preneoplastic lesions during dimethylhydrazine-induced colonic carcinogenesis. Eur. J. Clin. Invest. 1988; 18: 655-62.
15. Pretlow TP, O'Riordan MA, Kolman MF, Jurcisek JA. Colonic aberrant crypts in azoxymethane-treated F344 rats have decreased hexosaminidase activity. Am. J. Path. 1990; 136: 13-16.
16. Carderni G, Bianchim F, Mancina A, Spagnesi MT, Dolara P. Effect of dietary carbohydrates on the growth of dysplastic crypt foci in the colon of rats treated with 1,2-dimethylhydrazine. Cancer Res. 1991; 51: 3721-5.
17. Pereira MA, Barnes LH, Rassman VL, Kelloff GV, Steele VE. Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 1994; 15: 1049-54.
18. Wargovich MJ, Chen CD, Palmer C, Steele VE, Kelloff GJ. New agents for colon cancer prevention: Efficacy studies using carcinogen induced aberrant crypt foci in the rat. Proc. Am. Assoc. Cancer Res. 1992; 33: 168.
19. Metzger U, Meier J, Uhlschmid G, Weihe H. Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis. Col. Rect. 1984; 27: 366-9.
20. Hial V, Horakova Z, Shaff RE, Beaven M. Alteration of tumour growth by aspirin and indomethacin: Studies with two transplantable tumours in mouse. Eur. J. Pharmacol. 1976; 37: 367-76.
21. Reddy BS, Sharma C, Simi B et al. Metabolic epidemiology of colon cancer: Effect of dietary fiber on fecal mutagens and bile acids in healthy subjects. Cancer Res. 1987; 47: 644-8.
22. Wakabayashi K, Nagao M, Esumi H, Sugimura T. Food derived mutagens and carcinogens. Cancer Res. 1992; 52: S2092-2098.
23. Rogers AE, Nauss KM. Rodent models for carcinoma of the colon. Dig. Dis. Sci. 1985; 30: S87-102.
24. Verma AK, Ashendel CL, Boutwell RK. Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins, and tumour promotion caused by 12-O-Tetradecanoylphorbol-13-acetate. Cancer Res. 1980; 40: 308-15.